Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 25fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 15Etoposide 13Cyclosporine 13Mycophenolic Acid 12Busulfan 12Tacrolimus 11Filgrastim 11Antilymphocyte Serum 11Methotrexate 9Prednisone 8Dexamethasone 8nelarabine 7Radiotherapy 7Doxorubicin 7Vincristine 6Methylprednisolone 6Calcium Dobesilate 6Vorinostat 5Paclitaxel 5Lenalidomide 5Everolimus 5Carboplatin 5Bortezomib 5merphos 4aldesleukin 4Therapeutics 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡